Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1-style dose-escalation study of 211At-MABG in pheochromocytoma/paraganglioma
jRCT2021220012Phase 1Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of astatobenguane [211At] in pheochromocytoma and Paraganglioma (PGL) (3 cohorts), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 1 more. Started Oct 2022; status: active, not recruiting.
02
Drugs
astatobenguane [211At]
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on jRCT2021220012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021220012.